Generation Bio to Present at 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Generation Bio Co. (Nasdaq: GBIO) announced its participation in the virtual 40th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2022, from 8:15-8:55 a.m. ET. A live webcast of the presentation and Q&A will be accessible on the company's investor website, with a replay available for 30 days post-event. Generation Bio focuses on innovative genetic medicines aimed at treating rare and prevalent diseases, utilizing a novel delivery system and scalable manufacturing process to enhance treatment durability and efficiency.

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that the company will present at the virtual 40^th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 12, 2022.

Presentation Details
Date: Wednesday, Jan. 12, 2022
Time: 8:15-8:55 a.m. ET

A live webcast of the company presentation and Q&A session will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.

About Generation Bio
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.

For more information, please visit www.generationbio.com. 

Contact:

Investors 
Maren Killackey
Generation Bio
mkillackey@generationbio.com
541-646-2420

Media 

Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
617-903-8783

FAQ

What is the date and time of Generation Bio's presentation at the J.P. Morgan Healthcare Conference?

Generation Bio will present on January 12, 2022, from 8:15 to 8:55 a.m. ET.

How can I watch the Generation Bio presentation live?

The live webcast of Generation Bio's presentation will be available on their investor website.

Will there be a replay of Generation Bio's presentation available?

Yes, a replay of the presentation will be available for 30 days following the event.

What does Generation Bio focus on in its research and development?

Generation Bio is focused on innovating genetic medicines for rare and prevalent diseases.

What unique technology does Generation Bio utilize for drug delivery?

Generation Bio employs a unique cell-targeted lipid nanoparticle delivery system for its genetic medicines.